• Saturday,September 28,2024
gecos.fr
X

Cancer Biomarker Detection With Luminex Assays

$ 18.00

4.7 (480) In stock

Share

Luminex and Bio-Techne are working together to support the development of early diagnostic solutions that detect cancer earlier through the use of proteomics.
Charles Rosser, a research scientist and professor of biomedical sciences, has developed a multiplex test for early-stage bladder cancer using Luminex® xMAP® Technology. Bladder cancer affects over 570,000 people globally each year, and the Oncuria® test aims to detect bladder cancer, monitors for recurrence, and predicts which patients will benefit from the immunotherapy treatment. Current diagnostic assays lack sensitivity and do not provide a comprehensive view of the cancer’s molecular profile, but the Oncuria® test covers 10 glycoproteins to detect the biological signature of bladder cancer with sensitivity of 90% to 93% and specificity of 86% to 95%. The test received Breakthrough Device Designation status from the FDA and is currently available as a laboratory-developed test (LDT). In a recent clinical validation study involving about 350 patients, the test offered 93% sensitivity. Learn more about this major shift in the care of patients with bladder cancer.

MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel 3 - Cancer Multiplex Assay Circulating Cancer Biomarker

Luminex Cytokine Detection Service - Creative Proteomics

Luminex Platform Technology Thermo Fisher Scientific - FR

Bio-Techne on LinkedIn: Cancer Biomarker Detection With Luminex Assays

The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors, Journal of Nanobiotechnology

Cross-Reactivity of Bio-Plex Pro™ Human Cancer Biomarker Assays to Mouse Proteins

Luminex based screen of 16 urine proteins in bladder cancer. The dot

Hallmarks of Cancer ELISA Kits and Multiplex Immunoassays

Cancers, Free Full-Text

Improving Cancer Biomarker Detection with Multiplex Technology

How Luminex's XMAPTechnology helps cancer detection, Luminex Corporation - A Diasorin Company posted on the topic

A Fixation Protocol Compatible With RD Systems Luminex Assays Enabling Analysis With Infectious Samples

Immunoassays for Immuno-Oncology Research

R&D Systems: Luminex® Assays

Application of Luminex Technology in Clinical and Scientific Research - Creative Proteomics